Innovation in metabolomics to improve personalized healthcare

Annals of the New York Academy of Sciences

Volumn 1346, Issue 1, 2015, Pages 57-62

  Cacciatore, Stefano ^a   Loda, Massimo ^a,b,c,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Fatty acid; FFPE; Metabolomics; Oncogene; Prostate cancer

Indexed keywords

BIOLOGICAL MARKER; FORMALDEHYDE; PARAFFIN; XENOBIOTIC AGENT; TUMOR MARKER;

ARTICLE; CANCER CELL; ENZYME ACTIVITY; FATTY ACID SYNTHESIS; FEASIBILITY STUDY; GENE EXPRESSION; HUMAN; INFRARED SPECTROSCOPY; MASS SPECTROMETRY; METABOLOME; METABOLOMICS; MITOSIS; MOLECULE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ONCOGENE; PERSONALIZED MEDICINE; PROSTATE CANCER; RAMAN SPECTROMETRY; STEM CELL RESEARCH; INVENTION; MALE; METABOLISM; PROCEDURES; PROSTATE TUMOR; STANDARDS; TOTAL QUALITY MANAGEMENT; TRENDS;

HUMANS; INDIVIDUALIZED MEDICINE; INVENTIONS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; METABOLOME; METABOLOMICS; PROSTATIC NEOPLASMS; QUALITY IMPROVEMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 84941776656     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.12775     Document Type: Article

References (45)

1. International Human Genome Sequencing, C. 2004. Finishing the euchromatic sequence of the human genome. Nature 431: 931-945.
2. Bertini, I., et al. 2009. The metabonomic signature of celiac disease. J. Proteome Res. 8: 170-177.
3. Bertini, I., et al. 2012. Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer. Cancer Res. 72: 356-364.
4. Aimetti, M., et al. 2012. Metabonomic analysis of saliva reveals generalized chronic periodontitis signature. Metabolomics 8: 465-474.
5. Nicholson, J. K. & J. C. Lindon. 2008. Systems biology: metabonomics. Nature 455: 1054-1056.
6. Marshall, E. 2007. Metabolic research. Canadian group claims 'unique' database. Science 315: 583-584.
7. Wishart, D. S., et al. 2013. HMDB 3.0-The Human Metabolome Database in 2013. Nucl. Acids Res. 41: D801-D807.
8. Dunn, W. B., N. J. Bailey & H. E. Johnson. 2005. Measuring the metabolome: current analytical technologies. Analyst 130: 606-625.
9. German, J. B., B. D. Hammock & S. M. Watkins. 2005. Metabolomics: building on a century of biochemistry to guide human health. Metabolomics 1: 3-9.
10. Cacciatore, S., C. Luchinat & L. Tenori. 2014. Knowledge discovery by accuracy maximization. Proc. Natl. Acad. Sci. USA 111: 5117-5122.
11. Kettunen, J., et al. 2012. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat. Genet. 44: 269-276.
12. Cacciatore, S., et al. 2013. Effects of intra- and post-operative ischemia on the metabolic profile of clinical liver tissue specimens monitored by NMR. J. Proteome Res. 12: 5723-5729.
13. Beckonert, O., et al. 2010. High-resolution magic-angle-spinning NMR spectroscopy for metabolic profiling of intact tissues. Nat. Protoc. 5: 1019-1032.
14. Nelson, S.J., et al. 2013. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-(1)(3)C]pyruvate. Sci. Transl. Med. 5: 198ra108.
15. Lasch, P., et al. 2002. Infrared spectroscopy of human cells and tissue: detection of disease. Technol. Cancer Res. Treat. 1: 1-7.
16. Krafft, C., B. Dietzek & J. Popp. 2009. Raman and CARS microspectroscopy of cells and tissues. Analyst 134: 1046-1057.
17. Warburg, O. 1956. On respiratory impairment in cancer cells. Science 124: 269-270.
18. Shaw, R.J. 2006. Glucose metabolism and cancer. Curr. Opin. Cell Biol. 18: 598-608.
19. Priolo, C., et al. 2014. AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer. Cancer Res. 74: 7198-7204
20. Rossi, S., et al. 2003. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol. Cancer Res. 1: 707-715.
21. Liu, Y. 2006. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prost. Cancer Prost. Dis. 9: 230-234.
22. Zadra, G., et al. 2010. New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK. Clin. Cancer Res. 16: 3322-3328.
23. Li, J. & J.X. Cheng. 2014. Direct visualization of de novo lipogenesis in single living cells Sci. Rep. 4: 6807.
24. Liu, Y., L.S. Zuckier & N.V. Ghesani. 2010. Dominant uptake of fatty acid over glucose by prostate cells: a potential new diagnostic and therapeutic approach. Anticancer Res. 30: 369-374.
25. Baron, A., et al. 2004. Fatty acid synthase: a metabolic oncogene in prostate cancer? J. Cell Biochem. 91: 47-53.
26. Migita, T., et al. 2009. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J. Natl. Cancer Inst. 101: 519-532.
27. Epstein, J.I., M. Carmichael & A.W. Partin. 1995. OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. Urology 45: 81-86.
28. Zadra, G., C. Photopoulos & M. Loda. 2013. The fat side of prostate cancer. Biochim. Biophys. Acta 1831: 1518-1532.
29. Averna, T.A., et al. 2005. A decrease in 1H nuclear magnetic resonance spectroscopically determined citrate in human seminal fluid accompanies the development of prostate adenocarcinoma. J. Urol. 173: 433-438.
30. Serkova, N.J., et al. 2008. The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions. Prostate 68: 620-628.
31. Kurhanewicz, J., et al. 1995. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology 45: 459-466.
32. Nagarajan, R., et al. 2012. Correlation of Gleason scores with diffusion-weighted imaging findings of prostate cancer. Adv. Urol. 2012: 374805.
33. Selnaes, K. M., et al. 2013. Spatially matched in vivo and ex vivo MR metabolic profiles of prostate cancer-investigation of a correlation with Gleason score. NMR Biomed. 26: 600-606.
34. Giskeodegard, G. F., et al. 2013. Spermine and citrate as metabolic biomarkers for assessing prostate cancer aggressiveness. PLoS One 8: e62375.
35. Sreekumar, A., et al. 2009. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457: 910-914.
36. Meyer, T.E., et al. 2011. A reproducible and high-throughput HPLC/MS method to separate sarcosine from alpha- and beta-alanine and to quantify sarcosine in human serum and urine. Anal. Chem. 83: 5735-5740.
37. Khan, A.P., et al. 2013. The role of sarcosine metabolism in prostate cancer progression. Neoplasia 15: 491-501.
38. Yuan, M., et al. 2012. A positive/negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. Nat. Protoc. 7: 872-881.
39. Kelly, A.D., et al. 2011. Metabolomic profiling from formalin-fixed, paraffin-embedded tumor tissue using targeted LC/MS/MS: application in sarcoma. PLoS One 6: e25357.
40. Koppenol, W.H., P.L. Bounds & C.V. Dang. 2011. Otto Warburg's contributions to current concepts of cancer metabolism. Nat. Rev. Cancer 11: 325-337.
41. Dang, C.V. 1999. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell. Biol. 19: 1-11.
42. Gao, P., et al. 2009. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458: 762-765.
43. Eberlin, L.S., et al. 2014. Alteration of the lipid profile in lymphomas induced by MYC overexpression. Proc. Natl. Acad. Sci. USA 111: 10450-10455.
44. Escote, X. & L. Fajas. 2015. Metabolic adaptation to cancer growth: from the cell to the organism. Cancer Lett. 356: 171-175.
45. Scaglia, N., et al. 2014. De novo fatty acid synthesis at the mitotic exit is required to complete cellular division. Cell Cycle 13: 859-868.